Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy

Area of Science:

• Oncology
• Dermatology
• Cancer Biology

Background:

• Melanoma, the deadliest skin cancer, presents significant treatment challenges due to therapy resistance.
• While targeted therapies and immunotherapies have advanced melanoma treatment, cures remain elusive for most patients.
• Tumor heterogeneity, driven by distinct cell subpopulations and gene signatures, contributes to therapeutic resistance.

Purpose of the Study:

• To review the mechanisms of melanoma phenotype switching.
• To explore how cellular plasticity contributes to resistance against targeted therapies and immunotherapies.
• To highlight novel strategies for targeting melanoma plasticity and their clinical potential.

Main Methods:

• Literature review of studies on melanoma cellular plasticity.
• Analysis of mechanisms underlying phenotype switching in melanoma.
• Discussion of therapeutic resistance in relation to cellular plasticity.

Main Results:

• Melanoma exhibits cellular plasticity, termed phenotype switching, allowing transitions between proliferative and invasive states.
• Phenotype switching contributes to tumor heterogeneity and resistance to both targeted and immune-based therapies.
• Understanding these mechanisms is crucial for developing effective melanoma treatments.

Conclusions:

• Cellular plasticity is a key driver of melanoma progression and therapeutic resistance.
• Targeting melanoma phenotype switching presents a promising avenue for overcoming treatment challenges.
• Novel strategies aimed at plasticity could significantly improve clinical outcomes for melanoma patients.